World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 91 11716 11021 32 31 640 31955

Se-Hoon Lee publications per year

The chart shows the history of publications by Se-Hoon Lee between 1993 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Se-Hoon Lee published across 33 years, from 1993 to 2025, averaging 30.9 papers a year. Output peaked at 162 publications in 2023. 188 of the 1,021 publications appeared in the last two years.

No. of publications
50 100 150
Bar chart. Horizontal axis: year, 1993 to 2025. Vertical axis: number of publications, 0 to 162. Peak 162 publications in 2023. 1993: 2 publications 1994: 1 publication 1995: 1 publication 1996: 2 publications 1997: 0 publications 1998: 1 publication 1999: 0 publications 2000: 2 publications 2001: 3 publications 2002: 4 publications 2003: 13 publications 2004: 13 publications 2005: 12 publications 2006: 14 publications 2007: 23 publications 2008: 24 publications 2009: 32 publications 2010: 21 publications 2011: 26 publications 2012: 46 publications 2013: 45 publications 2014: 44 publications 2015: 53 publications 2016: 44 publications 2017: 39 publications 2018: 24 publications 2019: 45 publications 2020: 53 publications 2021: 37 publications 2022: 47 publications 2023: 162 publications 2024: 141 publications 2025: 47 publications
1993 2025

1,021 publications in total across all disciplines

View publications per year as a table
Se-Hoon Lee: publications per year, 1993 to 2025
Year Publications
1993 2
1994 1
1995 1
1996 2
1997 0
1998 1
1999 0
2000 2
2001 3
2002 4
2003 13
2004 13
2005 12
2006 14
2007 23
2008 24
2009 32
2010 21
2011 26
2012 46
2013 45
2014 44
2015 53
2016 44
2017 39
2018 24
2019 45
2020 53
2021 37
2022 47
2023 162
2024 141
2025 47
Total 1,021
Download as CSV

Se-Hoon Lee publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Se-Hoon Lee sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 621–640 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 640 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386 640
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Se-Hoon Lee D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Se-Hoon Lee sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 90–91 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922 91
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Se-Hoon Lee is affiliated with Sungkyunkwan University in South Korea and has a primary research focus in the field of Medicine. Their work spans several subfields including Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging, and Molecular Biology.

Their research concentrates on key topics such as:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Radiomics and Machine Learning in Medical Imaging
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies

Se-Hoon Lee has contributed to numerous publications, frequently appearing in the following venues:

  • Journal of Clinical Oncology
  • Cancer Research
  • Cancer Research and Treatment
  • Journal of Thoracic Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)

Their recent papers include:

  • Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma (2020, Nature Communications)
  • Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer (2020, Journal of Clinical Oncology)
  • Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer (2023, New England Journal of Medicine)
  • Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition (2021, Cell)
  • Lung adenocarcinoma promotion by air pollutants (2023, Nature)

Frequent co-authors collaborating with Se-Hoon Lee include:

  • Myung-Ju Ahn
  • Hyun Ae Jung
  • Jin Seok Ahn
  • Keunchil Park
  • Jong-Mu Sun

This body of work reflects ongoing research into cancer treatment mechanisms, lung cancer pathology, and advanced approaches in immunotherapy and molecular diagnostics.

Best Publications

  • Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    Laura Q.M. Chow;Robert Haddad;Shilpa Gupta;Amit Mahipal

  • Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

    Takashi Kojima;Manish A Shah;Kei Muro;Eric Francois

  • Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

    Kevin Litchfield;Kevin Litchfield;James L. Reading;Clare Puttick;Krupa Thakkar;Krupa Thakkar

  • Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma.

    Nayoung Kim;Nayoung Kim;Nayoung Kim;Hong Kwan Kim;Kyungjong Lee;Yourae Hong;Yourae Hong

  • Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

    Martin E Gore;Cezary Szczylik;Camillo Porta;Sergio Bracarda

  • The transcriptional landscape and mutational profile of lung adenocarcinoma

    Jeong Sun Seo;Young Seok Ju;Won Chul Lee;Jong Yeon Shin

  • Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

    June Koo Lee;Junehawk Lee;Sehui Kim;Soyeon Kim

  • Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

    Chiun Hsu;Se-Hoon Lee;Samuel Ejadi;Caroline Even

  • An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.

    Sung Kim;Do Hoon Lim;Jeeyun Lee;Won Ki Kang

  • DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

    Hyunchul Jung;Hong Sook Kim;Jeong Yeon Kim;Jong-Mu Sun

  • Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

    Heidi Greulich;Bethany Kaplan;Philipp Mertins;Tzu-Hsiu Chen

  • Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

    Jang Ho Cho;Sung Hee Lim;Ho Jung An;Ki Hwan Kim

  • Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.

    Bhumsuk Keam;Seock-Ah Im;Kyung-Hun Lee;Sae-Won Han

  • Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

    Jinhyun Cho;Hae Su Kim;Bo Mi Ku;Yoon-La Choi

  • Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer

    Song Ee Park;Se Hoon Lee;Jin Seok Ahn;Myung Ju Ahn

  • Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.

    Caicun Zhou;Sang We Kim;Thanyanan Reungwetwattana;Jianying Zhou

  • Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

    Se Hoon Lee;J. K. Lee;M. J. Ahn;D. W. Kim

  • Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer

    D. Y. Kim;Joo Hang Kim;S. H. Lee;T. Y. Kim

  • Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.

    Tae Min Kim;Tae Min Kim;Ahnah Song;Dong-Wan Kim;Dong-Wan Kim;Soyeon Kim

  • Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.

    Jeeyun Lee;Yeon Hee Park;Won Seog Kim;Seung-Sook Lee

Frequent Co-Authors

Dae Seog Heo
Dae Seog Heo Seoul National University Hospital
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Keunchil Park
Keunchil Park The University of Texas MD Anderson Cancer Center
Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University
Jin Seok Ahn
Jin Seok Ahn Sungkyunkwan University
Yung-Jue Bang
Yung-Jue Bang Seoul National University
Seock-Ah Im
Seock-Ah Im Seoul National University Hospital
Woong-Yang Park
Woong-Yang Park Samsung Medical Center
Doo Hyun Chung
Doo Hyun Chung Seoul National University
Ki-Hyun Kim
Ki-Hyun Kim Hanyang University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to several related online degrees and career pathways, especially for those seeking flexibility or specialization. Many healthcare professionals are now advancing their qualifications with affordable, flexible programs.

For nurses aiming to take on leadership roles, a 1 year dnp program online offers an accelerated option to earn a Doctor of Nursing Practice. Pharmacists, or those looking to become one, can consider accredited online pharmacy programs that provide convenience and cost-effective ways to obtain their credentials.

Another pathway to consider is in health information management. Accredited him programs are now available entirely online, equipping students with skills in digital health records and medical data.

For quick entry into the healthcare workforce, you might wonder how much is medical billing and coding school. These programs typically offer fast, affordable training and allow graduates to work in clinics, hospitals, and insurance companies.

Best Scientists Citing Se-Hoon Lee

Trending Scientists

Recently Published Articles